Kalorama: Cardiac Biomarker Testing Market Grows to Over $2 Billion
NEW YORK, June 27, 2016 /PRNewswire/ -- The market for tests using cardiac biomarkers grew to exceed $2 billion in 2015, according to Kalorama Information. The healthcare market research firm includes both cardiac markers commonly used for heart attack detection and more general biomarkers like cholesterol and coagulation tests. The healthcare market researcher's report, Cardiac Markers, provides market assessment, estimate and competitive analysis for tests for cardiovascular disease that use cardiac markers (CK-MB, troponin I, troponin T, myoglobin, brain natriuretic peptide (BNP), proBNP, high sensitive C-reactive protein (hsCRP), and homocysteine) and cardiovascular biomarkers.
Cardiac Markers can be found at Kalorama Information: http://www.kaloramainformation.com/Cardiac-Markers-10119142/.
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels and they include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, and congenital heart disease. CVDs are the number one cause of death globally; more people die annually from CVDs than from any other cause, according to the World Health Organization (WHO). Biomarkers are biological or biochemical molecules, or genetic changes, or other characteristics that can be measured, and that indicate or predict a condition, risk, or likely response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications.
"Driven by disease incidence, cardiac markers and cardiovascular biomarkers are in demand," said Bruce Carlson, Publisher of Kalorama Information. "Physicians use cardiac markers in two ways: acute care to diagnose a cardiac event in a hospital emergency room or chronic care to evaluate the risk of a cardiovascular event occurring and to monitor patients with a cardiovascular disease."
Markers such as CK-MB, troponin, and myoglobin had traditionally been used in acute care and tests such as those for cholesterol were used to evaluate risk. However, in the past few years cardiac markers have been revitalized with tests such as myeloperoxidase (MPO) brain natriuretic peptide (BNP) and proBNP becoming part of the acute care test menu and other tests such as high sensitive C-reactive protein (hsCRP), high sensitive troponin, homocysteine, Fatty Acid Binding Protein (FABP), Glycogen Phosphorylase isoenzyme BB (GPBB), urinary albumin, S-100 protein and hemoglobin A1c (hbA1c) now becoming part of the risk evaluation tool box.
Approximately 2.6 million people die of CVD each year in these seven countries: France, Germany, Italy, Japan, Spain, U.K., and the U.S. Thus, the market for CVD tests is concentrated in the developed world, with these countries accounting for a vast majority of product sales. The burgeoning middle class in Latin America, India, Asia Pacific and the Middle East account for additional growth in this market.
An aging population combined with advancements in technology is fueling growth as health care providers seek ways to meet the demand for high levels of service in a more cost effective manner. As diagnostic companies strive to provide platforms allowing for quick yet accurate diagnoses of patients, there is growing opportunity in the cardiac marker market. In the U.S., the Affordable Care Act (ACA), which is designed to advance healthcare accessibility, has helped to drive the market. The ACA encourages a shift toward payment based on the value of care.
New and developing markers are in preparation. It is possible that new cardiac panels will emerge, which combine markers of inflammation, ischemia, plaque instability, and necrosis.
There are currently a number of companies developing or marketing cardiac markers and cardiovascular biomarkers. The report contains profiles of many of the top competitors, including Abbott Laboratories, Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), bioMérieux SA, Quest Diagnostics, Roche Diagnostics, and Siemens Healthcare Diagnostics.
Cardiac Markers provides market assessment, estimate and competitive analysis for tests for cardiovascular disease (CVD) that use biomarkers, including the worldwide cardiovascular disease biomarkers diagnostic market – 2015 and 2020, selected in vitro diagnostic (IVD) markers of cardiovascular disease, selected biomarkers and biomarker panels for cardiovascular disease and companies developing/marketing these biomarkers, and selected lipid biomarkers, and companies developing/marketing these biomarkers.
The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.
Cardiac Markers can be found at Kalorama Information: http://www.kaloramainformation.com/Cardiac-Markers-10119142/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO
SOURCE Kalorama Information
Share this article